Cala Health Gains FDA Clearance for kIQ Plus Device

San Mateo, California & Chicago, Illinois, U.S. | April 15, 2026

Cala Health has announced a major regulatory milestone with the U.S. Food and Drug Administration (FDA) clearance of its next-generation Cala kIQ® Plus wearable device, designed to treat action hand tremor in patients with essential tremor (ET) and Parkinson’s disease (PD). This advancement represents a significant step forward in bioelectronic medicine and non-invasive neuromodulation therapies, offering a personalized and drug-free treatment option for millions of patients suffering from debilitating tremor conditions. The newly cleared system builds upon Cala’s proprietary Transcutaneous Afferent Patterned Stimulation (TAPS®) technology, introducing adaptive calibration and enhanced therapy modes to improve treatment precision and patient outcomes.

FDA Clearance Advances Wearable Neuromodulation Innovation

The FDA clearance of the Cala kIQ Plus system underscores the growing importance of medical devices in neurological disorder management, particularly for chronic conditions such as essential tremor and Parkinson’s disease. The device is indicated for the temporary relief of hand tremors, delivering targeted neurostimulation through a wearable wrist-based platform.

This regulatory milestone confirms that the device meets stringent standards for safety, efficacy, and quality, aligning with medical device regulatory pathways and compliance requirements. By advancing its TAPS technology, Cala continues to strengthen its position as a leader in non-invasive neuromodulation therapies, providing clinicians with innovative tools to manage movement disorders without reliance on pharmaceuticals or invasive procedures.

Next-Generation Features Enhance Personalized Therapy

The Cala kIQ Plus introduces several key innovations aimed at optimizing patient outcomes, including new therapy modes and adaptive calibration capabilities that tailor treatment to individual patient needs. These enhancements allow the device to dynamically adjust stimulation parameters based on tremor patterns, improving efficacy and ensuring a more personalized and responsive treatment experience.

The system is designed to be intuitive and user-friendly, enabling patients to control when and how therapy is delivered, thereby improving adherence and usability in real-world settings. Clinical data supporting the device’s performance will be presented at the American Academy of Neurology (AAN) 2026 meeting, where findings demonstrate increased responder rates and bilateral tremor improvement, further validating the technology’s clinical benefits.

Expanding Access to Non-Invasive Treatment Options

Essential tremor and Parkinson’s disease affect millions of individuals worldwide, significantly impacting daily activities and quality of life. Traditional treatment options often include medications or invasive procedures, which may not be suitable for all patients. The Cala kIQ Plus offers a non-invasive, wearable alternative that can be used at home, aligning with the growing trend toward digital health and remote therapeutic delivery.

The device is already available through the Veterans Affairs (VA) Health System and has Medicare coverage for eligible patients, improving accessibility and reducing barriers to care. Cala Health continues to pursue broader reimbursement pathways, aiming to expand access across commercial and Medicare Advantage plans.

Clinical and Commercial Implications for MedTech

The FDA clearance of Cala kIQ Plus highlights the rapid evolution of the MedTech sector, where innovations in neuroscience, wearable technology, and digital health are converging to transform patient care. By integrating advanced neuromodulation with personalized treatment algorithms, Cala is contributing to the development of next-generation therapies that prioritize patient experience and real-world effectiveness.

The company’s direct-to-home digital platform further enhances treatment delivery, enabling scalable and accessible care solutions for chronic neurological conditions. This milestone also reflects broader industry trends toward non-pharmacological interventions, particularly in areas where long-term medication use may present limitations or side effects.

The FDA clearance of the Cala kIQ Plus system marks a pivotal moment in the advancement of wearable neuromodulation therapies for movement disorders. By delivering a personalized, non-invasive solution for tremor management, Cala Health is redefining treatment paradigms and improving quality of life for patients with essential tremor and Parkinson’s disease. As the adoption of bioelectronic medicine continues to grow, innovations like Cala kIQ Plus are expected to play a critical role in shaping the future of healthcare, offering safe, effective, and patient-centric alternatives to traditional therapies.

Source: Cala Health press release